Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | CASP2 | P42575 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22898484 | 0.82 | GLP1R (0.44) | GLP1RALBL3MBTL1FOLH1SIRT5 | |
| SCHEMBL25944773 | 0.79 | GLP1R (0.37) | GLP1RALBL3MBTL1FOLH1SIRT5 | |
| SCHEMBL23330800 | 0.79 | ALB (0.42) | ALBL3MBTL1FOLH1TLR2SIRT5 | |
| SCHEMBL12982269 | 0.77 | GLP1R (0.60) | GLP1RTLR2CASP2SIRT2NOD1 | |
| SCHEMBL12982128 | 0.77 | GLP1R (0.60) | GLP1RTLR2CASP2SIRT2NOD1 | |
| SCHEMBL31688482 | 0.77 | OTC (0.41) | GLP1RFOLH1NOD1 | |
| SCHEMBL14500495 | 0.77 | ALB (0.43) | GLP1RALBFOLH1TLR2SIRT5 | |
| SCHEMBL12981896 | 0.77 | GLP1R (0.57) | GLP1RFOLH1SIRT5 | |
| SCHEMBL23330799 | 0.77 | ALB (0.41) | ALBL3MBTL1FOLH1TLR2SIRT5 | |
| SCHEMBL20672990 | 0.76 | GLP1R (0.52) | GLP1RALBFOLH1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357358-A1 | IL-7R-ALPHA-GAMMA BINDING COMPOUNDS | BLUEBIRD VENTURES I, L.P. | 2023-11-09 | — | — | US | disclosed |
| US-11746139-B2 | IL-7Rαγc binding compounds | MEDIKINE, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746139-B2 | IL-7Rαγc binding compounds | IL2RA, IL23R, IL6ST | GLP1R 287/4885ALB 2633/4885L3MBTL1 3021/4885 |
| US-20230357358-A1 | IL-7R-ALPHA-GAMMA BINDING COMPOUNDS | IL2RA, IL2, IL6ST | GLP1R 266/4885ALB 1918/4885L3MBTL1 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.